CS
TGTX icon

Candriam SCA’s TG Therapeutics TGTX Stock Holding History

Candriam SCA’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-353,983
Closed -$6.72M – 847
2021
Q4 		$6.72M Hold
353,983
– – 0.04% 305
2021
Q3 		$11.8M Hold
353,983
– – 0.08% 246
2021
Q2 		$13.7M Sell
353,983
-656,244
-65% -$25.8M 0.09% 238
2021
Q1 		$50.5M Hold
1,010,227
– – 0.42% 53
2020
Q4 		$52.6M Sell
1,010,227
-491,262
-33% -$16.6M 0.42% 53
2020
Q3 		$40.2M Sell
1,501,489
-45,582
-3% -$1.05M 0.38% 56
2020
Q2 		$30.1M Buy
1,547,071
+587,098
+61% +$9.46M 0.32% 74
2020
Q1 		$10.4M Buy
959,973
+57
+0% +$720 0.12% 205
2019
Q4 		$10.7M Buy
+959,916
New +$7.3M 0.11% 207
2019
Q3 		– Sell
-692,000
Closed -$5.96M – 813
2019
Q2 		$5.96M Hold
692,000
– – 0.07% 293
2019
Q1 		$5.56M Hold
692,000
– – 0.07% 302
2018
Q4 		$2.84M Hold
692,000
– – 0.04% 386
2018
Q3 		$3.88M Buy
692,000
+267,000
+63% +$3.05M 0.05% 374
2018
Q2 		$5.59M Buy
425,000
+65,000
+18% +$894K 0.09% 274
2018
Q1 		$5.11M Buy
360,000
+90,000
+33% +$1.15M 0.09% 279
2017
Q4 		$2.21M Buy
270,000
+50,000
+23% +$437K 0.04% 431
2017
Q3 		$2.61M Hold
220,000
– – 0.05% 401
2017
Q2 		$2.21M Sell
220,000
-95,000
-30% -$1.06M 0.04% 444
2017
Q1 		$3.67M Buy
315,000
+90,000
+40% +$646K 0.07% 322
2016
Q4 		$1.05M Buy
225,000
+55,000
+32% +$323K 0.02% 509
2016
Q3 		$1.32M Hold
170,000
– – 0.03% 443
2016
Q2 		$1.03M Sell
170,000
-37,000
-18% -$301K 0.03% 431
2016
Q1 		$1.75M Sell
207,000
-29,200
-12% -$256K 0.04% 344
2015
Q4 		$2.82M Sell
236,200
-25,000
-10% -$316K 0.08% 259
2015
Q3 		$2.63M Sell
261,200
-38,800
-13% -$578K 0.06% 301
2015
Q2 		$4.98M Sell
300,000
-30,000
-9% -$475K 0.1% 240
2015
Q1 		$5.11M Sell
330,000
-50,000
-13% -$757K 0.1% 250
2014
Q4 		$6.02M Buy
+380,000
New +$4.95M 0.13% 204

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Candriam SCA's TGTX Position: Q1 2022 in Review

Candriam SCA sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 353,983 shares — an estimated $6.72M sold.

Candriam SCA first reported a position in TGTX in Q4 2014 and held it in 28 quarters. The position peaked at $52.6M in Q4 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Candriam SCA reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Candriam SCA sold 353,983 TG Therapeutics shares in Q1 2022, an estimated $6.72M.
  • Candriam SCA first reported a position in TG Therapeutics in Q4 2014 and held it in 28 quarters.
  • Candriam SCA's TG Therapeutics position peaked at $52.6M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Candriam SCA's 13F filing for Q1 2022, filed 13 May 2022.